• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

TFF Pharmaceuticals announces US patent for DPI particle technology

TFF Pharmaceuticals said that it has received a notice of allowance for US Patent Application No. 12/778,795, titled, “Compositions and Methods of Making Brittle-Matrix Particles Through Blister Pack Freezing,” which covers technology related to the company’s DPI products for respiratory conditions.

Earlier this year, TFF announced that it had raised $14 million for development of API-only dry powder formulations based on thin film freezing (TFF) technology licensed from the University of Texas at Austin.

According to the company, the TFF technology has been used to create dry powder formulations of small molecules and biologics that are in development for diseases such as asthma, COPD, and lung infections.

TFF Pharmaceuticals CEO Glenn Mattes commented, “We are pleased to receive this key patent approval which secures the protection of our novel drug delivery system for years and will mean a significant competitive advantage. It is an important milestone in moving forward with commercializing a suite of drug products in development. The patent represents further validation of our proprietary thin film freezing technology. It expands our already extensive intellectual property portfolio of more than 30 patents. This is another progress step toward providing safer and more effective dry powder inhalation drug delivery options to benefit the global health community.”

University of Texas Professor Robert O. (Bill) Williams III, who developed the process, said, “The new patent is a foundational patent for TFF Pharmaceutical’s novel delivery system of dry powder drugs for inhalation of both biologic and small molecule drugs, allowing multiple opportunities to develop advanced drug products in a way not currently available. The patent complements and extends the company’s IP. It will enable TFF to leverage broad applications of the innovative technology for commercialization, providing alleviation of suffering and improved therapeutic outcomes for patients with serious lung diseases and conditions.”

Read the TFF Pharmaceuticals press release.

Share

published on July 11, 2018

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews